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BPSZ-BLISS is naturalistic and designed to obtain outcomes
data with minimum impact on BPSZ and clinical processees.
METHODS: Data are entered, using an Interactive Voice
Response System (IVRS), by MDs at baseline and at usual care
visits up to 12 +/- 2 months; subjects report self-measured BPs,
persistence, compliance, and treatment satisfaction at 3, 6, and
12 months. Final cohort characteristics are reported. RESULTS:
After 18 months, 10,067 eligible US subjects have been enrolled
by 734 IRB approved MDs. Subjects are 48% male, mean aged
56 (SD = 13) years, and 27% newly diagnosed with hyperten-
sion. Most are Caucasian (70%), or African-American (22%);
only 5% are Hispanic, or other (3%) ethnicity. Median diastolic
and systolic BPs qualifying subjects (without diabetes or kidney
disease) for study enrollment were 98 mmHg and 154 mmHg
respectively. In chronic hypertensives, most common anti-
hypertension medications prior to baseline were angiotensin
receptor blockers (ARB) or ARB combination (38%), calcium
channel blockers (CCB) or CCB combination (32%), beta block-
ers (BB) or BB combination (27%), or angiotensin converting
enzyme inhibitors (ACE I) or ACE I combination (24%), and
diuretics (18%). Automated IVRS validations have maintained
data quality (5% error on key variables). Completion of
patient follow-up is scheduled for June 2008. CONCLUSION:
An innovative design and automated data management and
quality control methodologies have been shown to be feasible to
collect MD and patient data in a nationwide health education
program. Baseline study data are available for comparison with
other real-world datasets.
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OBJECTIVE: To describe the trends of intra-hospital mortality,
length of stay (LOS) and readmissions of patients with acute
stroke at the National Healthcare Group (NHG), Singapore,
2000–2006. METHODS: All patients aged 21+ years dis-
charged with a primary diagnosis of stroke (ICD9CM 430-435)
from the three public hospitals in NHG from January 2000 to
December 2006 were studied. Data extracted from computer-
ized datamart included demographic characteristics; co-morbid
conditions; and outcomes of interest; i.e. LOS, intra-hospital
mortality, and readmissions within one, three, and six months
of discharge. Patients were stratiﬁed into hemorrhagic stroke
(HS), ischemic stroke (IS) and transient ischaemic attack (TIA).
Data were analysed by one-way ANOVA, logistic regression
and chi-square test using SPSSv15. RESULTS: During the
period 2000–2006, there was a total of 22,428 deaths and dis-
charges of patients with acute stroke. Prevalence of hyperten-
sion was highest in HS (>60%), with the rate decreasing
signiﬁcantly from 2000–2006 (p = 0.001). However, the preva-
lence of dyslipidaemia was highest among in IS, with a signiﬁ-
cant increase in rate in all during the period in all types of
stroke (p < 0.001). Overall, HS was associated with highest
intra-hospital mortality rate (95%CI: 22.3%–24.3%) and
longest average LOS (95%CI: 17.1–18.7 days). A signiﬁcant
increasing trend in average LOS (p < 0.001) was noted in both
HS and IS. Readmissions within the 1-month, 3-month, and
6-month all decreased signiﬁcantly over the period (p < 0.001).
The readmission rates within 1-month for HS and IS were
higher than that of TIA, while there were no difference in read-
mission rates within three (5%) and six (6%) months for all
stroke types. CONCLUSION: More studies into the causes of
increased LOS should be carried out. Targeted primary inter-
ventions are needed to address the high rates of hypertension
among those with IS and the increasing trend in dyslipidaemia
among all types of stroke.
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OBJECTIVE: Many patients with dyslipidemia fail to reach
treatment goals on the lowest dose of a single drug. We assessed
the effects of intensiﬁed lipid-modifying therapies on the
expected rates of coronary events among a cohort of 10,000
people aged 50+ years with established CHD and high non-HDL-
cholesterol levels. METHODS: This model-based analysis used
data from the recent SEACOAST clinical trial and a published
equation for secondary prevention of CHD from the Framing-
ham Heart Study (FHS), based on the total-cholesterol/HDL-C
ratio, to calculate the expected number of CHD events over ﬁve
years. Findings from the SEACOAST trial showed that patients
treated with a ﬁxed-dose extended release niacin/simvastatin
(ERN/S) combination had signiﬁcant improvements in non-
HDL-C, HDL-C, and triglyceride levels when compared to
patients treated with simvastatin therapy alone. Age, sex, and
coronary risk-factor data for patients with CHD and non-
HDL-C cholesterol >130 mg/dL were obtained from 1999–2002
NHANES. The drugs of interest included simvastatin alone and
ERN/S. The scenarios of interest reﬂected increasing the dose of
simvastatin or adding ERN to simvastatin. RESULTS: We esti-
mated that 1741 CHD events would occur over ﬁve years among
10,000 patients treated with 20 mg of simvastatin. The number
of CHD events would decrease by 8.9% with 1000/20 mg of
ERN/S. Relative to a maximum dose of 80 mg of simvastatin,
intermediate (1000/40 mg) and maximum doses (2000/40 mg) of
ERN/S would reduce CHD events by 4.9 and 11.1 percentage
points, respectively. CONCLUSION: Based on this FHS risk
model for a secondary prevention population with elevated
non-HDL cholesterol, intensifying lipid-modifying therapy with
selected ﬁxed-dose ERN/S combinations may reduce the number
of CHD events relative to the use of simvastatin monotherapy.
Conﬁrmation of the predicted clinical events of the ﬁxed-dose
combination in a secondary prevention patient population would
be useful.
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OBJECTIVE: Statin therapy is fundamental in cardiovascular
disease prevention. Beneﬁt of statin therapy is proportional to
low-density lipoprotein cholesterol reduction and no threshold
has been identiﬁed as a limitation below which beneﬁt is
reduced. Serious side-effects are infrequent, but the adverse
experience with the agent Cerivastatin justiﬁes scrutiny of the
relationship between therapeutic effect and the risk of side-
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effects. Meta-analysis of head-to-head comparisons represents a
robust method for anticipating the beneﬁt and risk of an emer-
gent statin, such as rosuvastatin, in comparison to an extensively
studied agent such as atorvastatin. METHODS: A systematic
literature search to identify head to head clinical studies of R and
A was conducted. Data were available for 30 comparisons of 1:1
dose ratios (R10mg vs. A10mg etc), 24 comparisons of 1:2 dose
ratios (R5mg vs. A10mg etc) and six comparisons of 1:4 dose
ratios (R5mg vs. A20mg etc). Treatment difference in beneﬁt (%
Low Density Lipoprotein-cholesterol [LDL-c] reduction) and
risk (odds ratios for myalgia, serious adverse events and with-
drawals due to adverse events, elevated Alaninaminotransferase
[ALT] (3xULN), and Creatine Kinase [CK] (>10xULN), were
estimated by meta-analysis (random effects) and presented in
beneﬁt risk planes. RESULTS: Analysis of 25 studies
(~24,000 pts) demonstrated rosuvastatin to be signiﬁcantly more
efﬁcacious than atorvastatin, for LDL-c reduction, at 1:1 and 1:2
dosage ratios. There were no signiﬁcant differences between
rosuvastatin and atorvastatin, at any dose ratio, for i) withdraw-
als due to adverse events, ii) myalgia, iii) serious adverse events,
iv) death, v) ALT > 3x upper limit of normal (ULN), and vi)
creatine kinase (CK) >10xULN. CONCLUSION: At 1:1 and 1:2
dose ratios, signiﬁcant additional reductions in LDL-c are
obtained by rosuvastatin at a comparable risk of the adverse
events presented.
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OBJECTIVE: To extend beyond the current approach of predict-
ing warfarin beneﬁt and harm independently in new atrial ﬁbril-
lation (AF) patients by reﬁning methods to identify predictors
of the four combined beneﬁt/harm outcome groups—i) no
stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no
stroke/no bleed. METHODS: We analyzed patient-level data
from the Atrial Fibrillation Investigators RCT database
(n = 9155) and an observational database of AF patients
managed by Kaiser Permanente Colorado (n = 5475). We classi-
ﬁed patients based on the four beneﬁt/harm outcome groups and
applied decision tree modeling (CART) and polytomous logistic
regression (PLR) to identify patient factors predicting each
outcome group. Statistical signiﬁcance was set at alpha = 0.05.
RESULTS: CART and PLR consistently identiﬁed age and war-
farin use as predictors for all outcome groups. Both techniques
identiﬁed predictors of stroke/no bleed and no stroke/bleed not
previously included in AF stroke and bleed risk-assessment tools
that predict these outcomes independently (e.g., CHADS2 and
HEMORR2HAGES). Methodology strengths and limitations
were evident. CART provides a visual algorithm approach to
risk. However, there is a lack of quantitative measurement (e.g.,
odds ratios [OR], conﬁdence intervals) for predictors. While PLR
results were thorough and predictor parameter estimates could
be converted to ORs to indicate strength of association, the result
of PLR is number-intensive. To calculate a patient’s probability
for each of the four outcome groups, the patient’s data must be
inputted into three separate equations. While both techniques
can be used to calculate an individual patient’s probability for
each outcome group, PLR likely has more scope for application
in a clinical setting. Once reﬁned, a clinical prediction rule could
be created based on identiﬁed predictors and their ORs.
CONCLUSION: While methods under study need further reﬁne-
ment, these individual patient data analyses provide a useful step
forward in the movement towards evidence-based individualiza-
tion of drug therapy.
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OBJECTIVE: Angina is relieved by CABG, PCI and stenting
procedures but reoccurs over time in a percentage of patients.
Little is known about the frequency of recurrent angina follow-
ing percutaneous and surgical procedures, the characteristics
which put a patient at risk for recurrent angina and the timing
of angina recurrence. METHODS: Patients enrolled in a large
national managed care plan with a claim for a CABG, PCI or
stent from January 1, 2003 to Decemeber 31, 2004 were selected
if they were 35 or older, and enrolled one year prior and one year
following their procedure. Patients were followed for one year
after their index procedure for medication use, angina diagnosis
by ICD-9 code and additional revascularization procedures.
RESULTS: Following selection criteria 18,240 patients were eli-
gible for analysis. The average age was 59 years, with 25% age
65 years and older. Most patients were male (78%). Of the
18,240 patients, 46% (8420) experienced angina (identiﬁed
by angina diagnosis and/or two or more nitrate prescriptions)
within a year following their index procedure. Of those patients
experiencing angina, approximately a third (30%/2904) had
another revascularization procedure following the angina diag-
nosis. The average time from initial procedure to second proce-
dure, after angina diagnosis, was 73 days, although there is a
wide range among patients (SD = 103 days). Risk factors for
having angina following a revascularization procedure were
younger age, female gender and having a PCI without a stent.
CONCLUSION: Angina reoccurs in a considerable percentage of
patients in the year following a percutaneous or surgical coro-
nary procedure. A third of patients experiencing angina have a
second procedure after experiencing recurrent angina.
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OBJECTIVE: Resistant hypertension is deﬁned as the failure to
reach blood pressure (BP) goals while treated at adequate doses
with three or more antihypertensive agents (AHYs) where one is
a diuretic. Clinical trials have found that 2–15% of treated
patients have resistant hypertension. The exact prevalence of
resistant hypertension in clinical practice is unknown. This
analysis evaluates the prevalence of resistant hypertension in a
real-world setting. METHODS: Hypertensive patients aged 18
and older were identiﬁed from the General Electric Electronic
Medical Records (EMR) database during the period of Novem-
ber 1, 2002 to November 30, 2005. Resistant hypertension was
deﬁned as a blood pressure reading over 140/90 mmHg (130/
80 mmHg for patients with diabetes or kidney disease) within
one year after the last AHY agent was prescribed during a
treatment observation window of November 1, 2003 to Novem-
ber, 2004. RESULTS: A total of 29,474 hypertensive patients
were identiﬁed with an average age of 63.3 years (SD  13.3)
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